cytotoxic T-lymphocyte associated protein 4

Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4)

Gene: CTLA4 | Wikidata ID: Q2907609 | Category: Gene

Overview

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4), encoded by the CTLA4 gene, is a transmembrane glycoprotein receptor expressed predominantly on the surface of activated T cells and regulatory T cells (Tregs). It functions as a critical negative regulator of T cell-mediated immune responses, acting as an inhibitory checkpoint that restrains excessive immune activation and maintains peripheral self-tolerance. CTLA-4 competes with the co-stimulatory receptor CD28 for binding to B7 ligands (CD80 and CD86) on antigen-presenting cells such as dendritic cells, but with far greater affinity, enabling it to outcompete CD28 and dampen T cell activation signals. This competitive inhibition is central to immune homeostasis: CTLA-4 signaling limits the proliferation and effector function of cytotoxic T cells while reinforcing the suppressive activity of regulatory T cells, thereby preventing autoimmunity.

The biological significance of CTLA-4 extends beyond immune tolerance to encompass a central role in tumor immune evasion. Because tumors can exploit CTLA-4-mediated suppression to escape immune surveillance, blocking this checkpoint has become a cornerstone of cancer immunotherapy. The anti-CTLA-4 monoclonal antibody ipilimumab was the first immune checkpoint inhibitor approved by regulatory agencies, establishing proof-of-concept for the broader class of checkpoint inhibitor therapies. CTLA-4 acts in close functional concert with other inhibitory receptors including PD-1, LAG3, TIM-3, and TIGIT, and its interplay with the PD-1/PD-L1 pathway has become a major axis of contemporary immuno-oncology research.

Focus of Latest Publications

Recent publications on cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have focused largely on its role as an immune checkpoint in cancer immunotherapy and on the consequences of CTLA-4 blockade. Several studies examined CTLA-4-targeting checkpoint inhibitors in the context of immune-related adverse events, including inflammatory arthritis, myasthenia gravis, myocarditis, and other severe toxicities. One report described a subset of regulatory T cells coexpressing CD137 and IL6R that was enriched in patients with immune checkpoint inhibitor-induced inflammatory arthritis; these atypical Tregs showed reduced suppressive function and a Th17-like proinflammatory phenotype, and anti-IL6R therapy with tocilizumab reduced their abundance while improving arthritis in a small cohort. Another case report highlighted the potentially fatal overlap of immune-related myasthenia gravis and myocarditis in a patient receiving durvalumab, underscoring the clinical risks associated with checkpoint inhibition.

Other recent work explored CTLA-4 in therapeutic combinations aimed at improving antitumor efficacy. In breast cancer, ex vivo analysis suggested that IL-2 reduced Treg-associated markers and decreased CTLA-4 expression in the tumor microenvironment, which was linked to activation of effector T cells and induction of tumor cell apoptosis. In colon cancer, cordycepin combined with CTLA-4 inhibitors improved antitumor efficacy in a mouse model, with multi-omics analyses implicating microbiome-mediated immunomodulation, increased responsiveness of tumor antigen-specific CD8+ T cells, reduced Treg immunosuppression, and suppression of the Bcl6 regulatory network. In head and neck squamous cell carcinoma, combining a CTLA4 monoclonal antibody with CCL21 was reported to enhance T-cell activation in the tumor microenvironment and modulate JAK/STAT pathway proteins, suggesting a strategy to optimize CTLA-4 blockade.

CTLA-4 also appeared in broader translational and biomarker-oriented studies. A melanoma prognostic signature included CTLA4 among eight immune-related genes and was associated with survival, immune cell infiltration, and immune checkpoint expression, although its predictive value for treatment response remained unvalidated. In colorectal cancer, a review emphasized tumor-intrinsic and immune checkpoint signaling involving PD-1 and CTLA-4 as central to immune evasion and as key therapeutic targets in biologically distinct CRC subsets. In hepatocellular carcinoma, a study protocol proposed cadonilimab, a dual inhibitor targeting PD-1 and CTLA-4, combined with lenvatinib and stereotactic body radiotherapy as conversion therapy for unresectable or potentially resectable disease.

Across these publications, CTLA-4 was consistently framed as a central regulator of antitumor immunity and immune tolerance. The studies collectively linked CTLA-4 blockade to improved immune activation and tumor control, while also emphasizing the risk of immune-related toxicity and the need for strategies that preserve antitumor benefit without exacerbating autoimmunity.

Key Publications

NEWJul Checkpoint inhibitors create rogue regulatory T cells. (The Journal of clinical investigation, 2026, PMID 42383349): "...treatment with PD-1, PD-L1, or CTLA-4 inhibitors in patients with cancer."
NEWJul Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. (Immunologic research, 2026, PMID 42384108): "By inhibiting proteins such as programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), these agents enhance the immune response against cancer cells."
May Vasoactive intestinal peptide associated 8-gene signature with prognostic and immune associations in melanoma. (Medicine, 2026, PMID 42216340): "In melanoma, we identified an 8-gene signature (CD28, CD80, CD86, CTLA4, FAS, IFNG, IL10, and IL12A) associated with survival."
May Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg/CTLA-4/Blimp-1/caspase-3. (Scientific reports, 2026, PMID 42192107): "Results of network pharmacology illustrated that there were 35 common targets including CD4, CTLA-4 and caspase 3."
May Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity. (Science advances, 2026, PMID 42090506): "Checkpoint inhibitors targeting PD-1 and CTLA-4 have transformed cancer therapy."
Apr Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types. (Gut microbes, 2026, PMID 42026803): "Targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) with immune checkpoint inhibitors (ICIs) has improved survival across multiple cancer types, but the variability in patient response highlights the need for better predictive biomarkers."
Apr Cadonilimab Plus Lenvatinib Combined with Stereotactic Body Radiotherapy for Conversion Therapy in Unresectable or Potentially Resectable Hepatocellular Carcinoma: A Study Protocol. (Current medical science, 2026, PMID 41954707): "Given these advancements, this study aims to investigate the efficacy and safety of cadonilimab (a dual immune checkpoint inhibitor targeting PD-1 and CTLA-4) plus lenvatinib (a multi-targeted tyrosine kinase inhibitor) combined with stereotactic body radiotherapy (SBRT), with the goal of achieving conversion therapy for potentially resectable HCC and prolonging survival for unresectable HCC."
Apr Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling. (Expert opinion on biological therapy, 2026, PMID 41925220): "...including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)..."
Apr Mechanistic insights into cordycepin-enhanced CTLA-4 blockade efficacy via Eubacterium rectale-mediated immunomodulation in colon cancer. (International immunopharmacology, 2026, PMID 41722537): "This study investigates the synergistic antitumor effects of cordycepin combined with CTLA-4 inhibitors, focusing on their ability to reshape the gut microbiome."
Jul Augmenting Chemokine CCL21 Enhances the Effectiveness of CTLA4 Blockade Immunotherapy for Head and Neck Squamous Carcinoma. (Molecular cancer therapeutics, 2026, PMID 41194506): "Recent studies have demonstrated promising outcomes in the treatment of head and neck squamous cell carcinoma (HNSCC) through immune checkpoint cytotoxic T lymphocyte antigen 4 (CTLA4) blockade."